Trial Profile
A multicenter, retrospective, longitudinal study evaluating efficacy and safety of Imatinib treatment in patients with Chronic Myeloid Leukemia: a study from Algerian working group (GAT-LMC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 25 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology